Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11851426 Bicyclic amines as CDK2 inhibitors

Patent 11851426 was granted and assigned to Incyte on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Incyte
Incyte
0
Date Filed
October 9, 2020
0
Date of Patent
December 26, 2023
0
Patent Applicant
Incyte
Incyte
0
Patent Application Number
17067203
0
Patent Citations
‌
US Patent 8008449 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
0
‌
US Patent 8168757 PD-1 binding proteins
0
‌
US Patent 8183242 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
0
‌
US Patent 8217149 Anti-PD-L1 antibodies, compositions and articles of manufacture
0
‌
US Patent 8431596 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
0
‌
US Patent 8865732 Heterocyclic compounds and uses thereof
0
‌
US Patent 9073927 Inhibitors of PI3 kinase
0
‌
US Patent 9850244 Method for preparing Palbociclib
0
‌
US Patent 10308644 Heterocyclic compounds as immunomodulators
0
‌
US Patent 11066404 Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
0
•••
Patent Citations Received
‌
US Patent 11981671 Bicyclic pyrazolyl amines as CDK2 inhibitors
0
Patent Inventor Names
Liangxing Wu
0
Wenqing Yao
0
Ding-Quan Qian
0
Yingda Ye
0
Zhenwu Li
0
Sarah Winterton
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11851426
0
Patent Primary Examiner
‌
Susanna Moore
0
CPC Code
‌
C07D 471/04
0

Find more entities like US Patent 11851426 Bicyclic amines as CDK2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.